SLC22A12
Solute carrier family 22 member 12
As of the edition of 20 October 2026, SLC22A12 (solute carrier family 22 member 12, UniProt Q96S37) has 10 drugs tested at it and 11 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96S37
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 28
- Disease areas
- Nutrition and metabolism; Bones, joints and muscles; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Hormones; Heart and blood vessels; Digestive system
- Registered trials of its drugs
- 103
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 1 |
| Stopped | 1 |
| Status not established | 2 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Verinurad | Active | Phase 2 | none listed |
| Lesinurad | Marketed | Phase 3 | Ends 2032 |
| Dotinurad | Marketed | Phase 4 | none listed |
| SHR-4640 | Active | Phase 3 | none listed |
| Arhalofenate | Went quiet | Phase 3 | none listed |
| Benzbromarone | Marketed | Phase 4 | none listed |
| Epaminurad | Status not established | Phase 3 | none listed |
| PF-06743649 | Stopped | Phase 1 | none listed |
| URC102 | Status not established | Phase 2 | none listed |
| Sulfinpyrazone | Marketed | No phase stated | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 5 |
| Undetermined | 1 |
| Total on the list | 11 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Ironwood Pharmaceuticals | Route B |
| Pfizer | Route A |
The other 8 companies at SLC22A12
In the product11 companies in all; 8 are not named here, and no score is.
See the 11 companies at SLC22A12, ranked, with the facts behind eachRequest access. Nothing is shown until you do.